Nose-to-brain delivery has a rat problem

Nick Taylor at in-PharmaTechnologist.com filed an interesting report on nose-to-brain drug delivery from the American Association of Pharmaceutical Scientists' annual meeting in New Orleans. The nose remains a promising route to the central nervous system, but the problem is that, so far, most of the testing has been done on rats, which have very different noses than humans. Taylor mentions OptiNose, which we profiled in September, and its breath-activated device. Studies suggest the device is capable of nose-to-brain delivery, said Per Djupesland, the company's chief scientific officer. Unfortunately, the rat-human problem is there again, so validation is difficult. With a rat, you can sacrifice it to view the brain. This is frowned upon in human trials. Report

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.